Actively Recruiting
Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain
Led by Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy) · Updated on 2025-05-09
36
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Neuropathic pain is frequent and drugs relieves only 50% of the patients. Repetitive transcranial magnetic stimulation (rTMS) at high frequency (HF, usually 10Hz) applied on the primary motor cortex (M1) is an effective treatment of neuropathic pain. For the treatment of chronic pain, the 'classical' HF-rTMS protocol (CHF-rTMS) include one daily session for one or two weeks as an induction phase of treatment followed by a weekly session to produce analgesic effects. However, another type of protocol is based on a more spaced repetition of HF-rTMS sessions (SHF-rTMS), including intervals of several days or weeks between two sessions, but also resulting in a significant pain relief. However, CHF-rTMS and SHF-rTMS have never been compared regarding their analgesic efficacy. Alongside with pain, depression is the other clinical condition for which HF-rTMS is proposed as an effective therapeutic strategy. Another type of rTMS paradigm, called "accelerated intermittent theta burst stimulation" (ACC-iTBS) protocol has been recently proposed for the treatment of depression, combining a high number of pulses delivered per session and a high number of short-duration sessions grouped into a few days of stimulation. However, this type of protocol has never been applied for the treatment of chronic pain patients. Thus, for the first time we propose to compare in a pilot study the efficacy of three different rTMS protocols for the treatment of chronic neuropathic: CHF-rTMS, SHF-rTMS, and ACC-iTBS. In this study, two protocols two rTMS protocols (CHF-rTMS and ACC-iTBS) will share the same high total number of TMS pulses (i.e. 30 000 pulses) versus an rTMS protocol (SHF-rTMS) based on a lower total number of TMS pulses (i.e. 6 400 pulses), while one protocol (CHF-rTMS) will include a higher number of days of stimulation (i.e. 10 days) compared to the two other protocols (ACC-iTBS and SHF-rTMS) (i.e. 4 days). In all cases, the motor cortical target and the intensity of stimulation will the same. Thus, this study will be able to appraise the respective influence of the number of pulses delivered (the higher the number, the greater the effect) and the number of sessions (the higher the number, the more restrictive the implementation of treatment). That is to say that the new ACC-iTBS protocol could be an optimal compromise of a more efficacious and more easy-to-perform rTMS protocol for the treatment of patients with chronic pain.
CONDITIONS
Official Title
Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Definite peripheral neuropathy confirmed by clinical and neurophysiological evaluation for at least 6 months
- Neuropathic pain clearly related to neuropathy with a DN4 questionnaire score of 4 or higher
- Average daily ongoing pain intensity of 4 or higher on a 0-10 numerical rating scale
- Age between 18 and 80 years
- Affiliation with the social security system
- Ability to provide signed informed consent
You will not qualify if you...
- Presence of neurological or psychiatric illnesses such as neurodegenerative disorders, migraine, epilepsy, stroke, or tumor
- Contraindications to transcranial magnetic stimulation (e.g., intracranial ferromagnetic material)
- Drug-resistant or active epilepsy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henri Mondor University Hospital
Créteil, Île-de-France Region, France, 94000
Actively Recruiting
Research Team
J
Jean-Pascal Lefaucheur, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here